A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action

Reviews in Medical Virology

Volumn 26, Issue 4, 2016, Pages 242-250

  Yang, Jie ^a,c   Liu, Shuwen ^a   Du, Lanying ^c   Jiang, Shibo ^b,c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE INHIBITOR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DEVELOPMENTAL STAGE; DISEASE COURSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; LIFE CYCLE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; VIRUS STRAIN;

EID: 84978871028     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1879     Document Type: Review

References (70)

1. Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Emerging Infectious Diseases 2006; 12: 15–22. DOI:10.3201/eid1201.050979.
2. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325: 197–201. DOI:10.1126/science.1176225.
3. Organization WH. Pandemic (H1N1) 2009—update 112. 2010.
4. Claas EC, Osterhaus AD, van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351: 472–477. DOI:10.1016/s0140-6736(97)11212-0.
5. Update: WHO-confirmed human cases of avian influenza A (H5N1) infection, November 2003-May 2008. Weekly Epidemiological Record 2008; 83: 415–420.
6. Herfst S, Schrauwen EJ, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012; 336: 1534–1541. DOI:10.1126/science.1213362.
7. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. New England Journal of Medicine 2013; 368: 1888–1897. DOI:10.1056/NEJMoa1304459.
8. Lee YJ, Kang HM, Lee EK, et al. Novel reassortant influenza A(H5N8) viruses, South Korea, 2014. Emerging Infectious Diseases 2014; 20: 1087–1089. DOI:10.3201/eid2006.140233.
9. Zhao K, Gu M, Zhong L, et al. Characterization of three H5N5 and one H5N8 highly pathogenic avian influenza viruses in China. Veterinary Microbiology 2013; 163: 351–357. DOI:10.1016/j.vetmic.2012.12.025.
10. De Clercq E. Antiviral agents active against influenza A viruses. Nature Reviews Drug Discovery 2006; 5: 1015–1025. DOI:10.1038/nrd2175.
11. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 2007; 73: 228–231. DOI:10.1016/j.antiviral.2006.10.004.
12. Moscona A. Neuraminidase inhibitors for influenza. New England Journal of Medicine 2005; 353: 1363–1373. DOI:10.1056/NEJMra050740.
13. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175–1181. DOI:10.1016/s0140-6736(05)67338-2.
14. Keyser LA, Karl M, Nafziger AN, Bertino JS Jr. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Archives of Internal Medicine 2000; 160: 1485–1488.
15. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR - Recommendations and Reports 2005; 54: 1–40.
16. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR & Recommendations and Reports 2011; 60: 1–24.
17. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845–1850.
18. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. New England Journal of Medicine 1997; 337: 874–880. DOI:10.1056/nejm199709253371302.
19. Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation. Journal of Infection and Chemotherapy 2014; 20: 689–695. DOI:10.1016/j.jiac.2014.07.006.
20. Shobugawa Y, Saito R, Sato I, et al. Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. Journal of Infection and Chemotherapy 2012; 18: 858–864. DOI:10.1007/s10156-012-0428-1.
21. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors—a review. Antiviral Research 2000; 47: 1–17.
22. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108. DOI:10.1038/4371108a.
23. Sheu TG, Fry AM, Garten RJ, et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008–2010. Journal of Infectious Diseases 2011; 203: 13–17. DOI:10.1093/infdis/jiq005.
24. Samji T. Influenza A: understanding the viral life cycle. Yale Journal of Biology and Medicine 2009; 82: 153–159.
25. Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Reviews in Medical Virology 2002; 12: 159–166. DOI:10.1002/rmv.352.
26. Nayak DP, Hui EK, Barman S. Assembly and budding of influenza virus. Virus Research 2004; 106: 147–165. DOI:10.1016/j.virusres.2004.08.012.
27. Lin YP, Gregory V, Collins P, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? Journal of Virology 2010; 84: 6769–6781. DOI:10.1128/jvi.00458-10.
28. Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic acid receptors. Journal of Virology 2012; 86: 13371–13383. DOI:10.1128/jvi.01426-12.
29. Gulati S, Smith DF, Cummings RD, et al. Human H3N2 influenza viruses isolated from 1968 to 2012 show varying preference for receptor substructures with no apparent consequences for disease or spread. PLoS One 2013; 8: e66325.
30. Chambers BS, Li Y, Hodinka RL, et al. Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses. Journal of Virology 2014; 88: 10986–10989. DOI:10.1128/JVI.01077-14.
31. Lee HK, Tang JW, Kong DH, et al. Comparison of mutation patterns in full-genome A/H3N2 influenza sequences obtained directly from clinical samples and the same samples after a single MDCK passage. PLoS One 2013; 8: e79252. DOI:10.1371/journal.pone.0079252.
32. Mishin VP, Sleeman K, Levine M, et al. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses. Antiviral Research 2014; 101: 93–96. DOI:10.1016/j.antiviral.2013.11.001.
33. Hooper KA, Bloom JD. A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein. Journal of Virology 2013; 87: 12531–12540. DOI:10.1128/jvi.01889-13.
34. Mohr PG, Deng YM, McKimm-Breschkin JL. The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding. Virology Journal 2015; 12: 67. DOI:10.1186/s12985-015-0295-3.
35. Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Science 1994; 3: 1687–1696. DOI:10.1002/pro.5560031007.
36. Cohen M, Zhang XQ, Senaati HP, et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virology Journal 2013; 10: 321. DOI:10.1186/1743-422x-10-321.
37. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. Journal of Virology 2004; 78: 12665–12667. DOI:10.1128/jvi.78.22.12665-12667.2004.
38. Ohuchi M, Asaoka N, Sakai T, Ohuchi R. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes and Infection 2006; 8: 1287–1293. DOI:10.1016/j.micinf.2005.12.008.
39. Su B, Wurtzer S, Rameix-Welti MA, et al. Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS One 2009; 4: e8495. DOI:10.1371/journal.pone.0008495.
40. Chen Q, Huang S, Chen J, Zhang S, Chen Z. NA proteins of influenza A viruses H1N1/2009, H5N1, and H9N2 show differential effects on infection initiation, virus release, and cell-cell fusion. PLoS One 2013; 8: e54334. DOI:10.1371/journal.pone.0054334.
41. Hooper KA, Crowe JE Jr, Bloom JD. Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice. Journal of Virology 2015; 89: 3737–3745. DOI:10.1128/jvi.00012-15.
42. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381: 2273–2279. DOI:10.1016/s0140-6736(13)61125-3.
43. Takashita E, Meijer A, Lackenby A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Research 2015; 117: 27–38. DOI:10.1016/j.antiviral.2015.02.003.
44. Baranovich T, Saito R, Suzuki Y, et al. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. Journal of Clinical Virology 2010; 47: 23–28. DOI:10.1016/j.jcv.2009.11.003.
45. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrobial Agents and Chemotherapy 2010; 54: 1834–1841. DOI:10.1128/aac.01608-09.
46. Liu S, Wu S, Jiang S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Current Pharmaceutical Design 2007; 13: 143–162.
47. Este JA, Telenti A. HIV entry inhibitors. Lancet 2007; 370: 81–88. DOI:10.1016/s0140-6736(07)61052-6.
48. Yang J, Li M, Shen X, Liu S. Influenza A virus entry inhibitors targeting the hemagglutinin. Viruses 2013; 5: 352–373. DOI:10.3390/v5010352.
49. Xia S, Liu Q, Wang Q, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Research 2014; 194: 200–210. DOI:10.1016/j.virusres.2014.10.007.
50. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New England Journal of Medicine 2003; 348: 2175–2185. DOI:10.1056/NEJMoa035026.
51. Yoshimoto J, Kakui M, Iwasaki H, Sugimoto H, Fujiwara T, Hattori N. Identification of amino acids of influenza virus HA responsible for resistance to a fusion inhibitor, Stachyflin. Microbiology and Immunology 2000; 44: 677–685.
52. Liu S, Li R, Zhang R, et al. CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry. European Journal of Pharmacology 2011; 660: 460–467. DOI:10.1016/j.ejphar.2011.04.013.
53. Yang J, Li L, Tan S, et al. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection. Fitoterapia 2012; 83: 348–355. DOI:10.1016/j.fitote.2011.11.016.
54. Ding N, Chen Q, Zhang W, Ren S, Guo Y, Li Y. Structure-activity relationships of saponin derivatives: a series of entry inhibitors for highly pathogenic H5N1 influenza virus. European Journal of Medicinal Chemistry 2012; 53: 316–326. DOI:10.1016/j.ejmech.2012.04.022.
55. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303: 41–44.
56. Air GM, Laver WG. The neuraminidase of influenza virus. Proteins 1989; 6: 341–356.
57. Varghese JN, McKimm-Breschkin JL, Caldwell JB, et al. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992; 14: 327–332.
58. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443: 45–49.
59. Mohan S, McAtamney S, Haselhorst T, von Itzstein M, Pinto BM. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles. Journal of Medicinal Chemistry 2010; 53: 7377–7391. DOI:10.1021/jm100822f.
60. Shan Y, Ma Y, Wang M, Dong Y. Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents. Current Medicinal Chemistry 2012; 19: 5885–5894.
61. Mohan S, Kerry PS, Bance N, Niikura M, Pinto BM. Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor. Angewandte Chemie International Edition in English 2014; 53: 1076–1080. DOI:10.1002/anie.201308142.
62. Cheng CK, Tsai CH, Shie JJ, Fang JM. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Future Medicinal Chemistry 2014; 6: 757–774. DOI:10.4155/fmc.14.30.
63. D'Souza C, Kanyalkar M, Joshi M, et al. Search for novel neuraminidase inhibitors: design, synthesis and interaction of oseltamivir derivatives with model membrane using docking, NMR and DSC methods. Biochimica et Biophysica Acta 2009; 1788(9): 1740–1751. DOI:10.1016/j.
64. Adabala PJ, LeGresley EB, Bance N, et al. Exploitation of the catalytic site and 150 cavity for design of influenza A neuraminidase inhibitors. Journal of Organic Chemistry 2013 Nov 1; 78(21): 10867–10877. DOI:10.1021/jo401854w.
65. Chong AK, Pegg MS, Taylor NR, et al. Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus. European Biochemical 1992; 207: 335–343. DOI:10.1111/j.1432-1033.1992.tb17055.x.
66. Stevens J, Chen LM, Carney PJ, et al. Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. Journal of Virology 2010; 84: 8287–8299. DOI:10.1128/JVI.00058-10.
67. Ghate AA, Air GM. Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design. European Journal of Biochemistry 1998; 258: 320–331. DOI:10.1021/jo401854w.
68. Dunning J, Baillie JK, Cao B, Hayden FG. Antiviral combinations for severe influenza. Lancet Infectious Diseases 2014; 14: 1259–1270. DOI:10.1016/s1473-3099(14)70821-7.
69. Deryabin PG, Galegov GA, Konstantinova ID, Muzyka IS, Miroshnikov AI, L'Vov DK. The combination of ribavirin and ozeltamivir effectively inhibits reproduction of influenza A virus resistant to rimantadine (amantadine) in vitro and in vivo. Doklady Biochemistry and Biophysics 2014; 455: 80–83. DOI:10.1134/s1607672914020100.
70. Nguyen JT, Hoopes JD, Smee DF, et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrobial Agents and Chemotherapy 2009; 53: 4115–4126. DOI:10.1128/aac.00476-09.